No Data
No Data
Express News | Mural Oncology Reaffirms Guidance That Its Cash & Equivalents Are Expected To Fund Its Operations Into Q4 Of 2025
Express News | Mural Oncology Q2 2024 GAAP EPS $(1.86) Up From $(3.01) YoY
Express News | Mural Oncology PLC -Qtrly Shr Loss $1.86
Express News | Mural Oncology PLC: Reiterates Guidance on Projected Cash Runway Into Q4 2025
Express News | Mural Oncology PLC - Candidate Nominations for Mural's Il-18 and Il-12 Programs Are Expected Later This Year
Express News | Mural Oncology - on Track to Report Readouts From Mural's Lead Asset, Nemvaleukin Alfa, in Two Late-Stage Clinical Trials in 1H 2025